What is HC Wainwright’s Estimate for RAPP Q3 Earnings?

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Rapport Therapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($1.36) per share for the quarter. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($4.51) EPS, FY2027 earnings at ($6.80) EPS, FY2028 earnings at ($8.40) EPS, FY2029 earnings at ($8.08) EPS and FY2030 earnings at ($6.96) EPS.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07).

A number of other equities research analysts have also commented on RAPP. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. William Blair assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. Truist Financial started coverage on Rapport Therapeutics in a report on Monday, May 18th. They set a “buy” rating and a $56.00 target price for the company. Finally, Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Rapport Therapeutics Stock Performance

Shares of RAPP stock opened at $46.98 on Monday. Rapport Therapeutics has a 52 week low of $13.86 and a 52 week high of $48.00. The company’s 50 day moving average price is $39.97 and its two-hundred day moving average price is $34.75. The company has a market capitalization of $2.25 billion, a P/E ratio of -15.45 and a beta of 0.97.

Institutional Trading of Rapport Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TRV GP V LLC bought a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $261,709,477,000. Goldman Sachs Group Inc. increased its stake in shares of Rapport Therapeutics by 23.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock worth $91,077,000 after purchasing an additional 579,903 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at about $112,500,000. Vanguard Group Inc. raised its holdings in shares of Rapport Therapeutics by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock valued at $55,151,000 after purchasing an additional 191,219 shares during the period. Finally, Johnson & Johnson acquired a new stake in Rapport Therapeutics in the 2nd quarter valued at about $74,360,823,000.

Insider Buying and Selling

In other news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total transaction of $743,808.60. Following the sale, the insider owned 6,280,525 shares in the company, valued at $251,535,026.25. This represents a 0.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Abraham Ceesay sold 2,210 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $42.11, for a total value of $93,063.10. Following the completion of the sale, the chief executive officer directly owned 537,607 shares of the company’s stock, valued at approximately $22,638,630.77. The trade was a 0.41% decrease in their position. The SEC filing for this sale provides additional information. 12.48% of the stock is owned by company insiders.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.